IL2 and pancreatic neoplasm: To evaluate the therapeutic efficacy of the ex vivo-expanded NK cells in vivo, MIA PaCa-2 orthotopic pancreatic tumor-bearing mice were treated with NK cells (2 × 107 cells via intravenous injection), IL-2 (250 U via intravenous injection), or gemcitabine (100 mg/kg via intraperitoneal injection).